Alectinib

證據等級: L5

預測適應症: 10 個

Alectinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis

One-Sentence Summary

Alectinib is a second-generation, highly selective ALK (Anaplastic Lymphoma Kinase) tyrosine kinase inhibitor, with established global clinical use in ALK-positive non-small cell lung cancer (NSCLC), though it is not currently registered with the TGA in Australia. The TxGNN model predicts it may be effective for Gingival Fibromatosis (Fibromatosis, Gingival), however, no clinical trials or supporting publications currently exist for this specific indication, and the biological rationale is assessed as extremely low — this prediction is most likely a knowledge graph artefact rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	ALK-positive non-small cell lung cancer (NSCLC)
Predicted New Indication	Fibromatosis, Gingival (Gingival Fibromatosis)
TxGNN Prediction Score	99.97%
Evidence Level	L5
Australia Market Status	Not Marketed (0 ARTG entries)
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this Evidence Pack. Based on published clinical pharmacology, Alectinib is a second-generation, ATP-competitive inhibitor of ALK, with additional activity against RET and ROS1 kinases. It works by blocking the constitutively active EML4-ALK fusion protein found in approximately 3–5% of NSCLC patients, preventing downstream tumour cell proliferation and survival signalling. Its clinical efficacy in ALK-positive NSCLC has been robustly established across multiple global Phase 3 trials (ALEX, J-ALEX, ALESIA) and is supported by a substantial body of peer-reviewed literature — though none of this evidence relates to the predicted indication assessed here.

Gingival fibromatosis (GF) is a rare, typically hereditary condition characterised by progressive fibrous overgrowth of gingival tissue. Its primary known genetic drivers are mutations in the SOS1 gene (GINGF1 locus) and related hereditary loci, governing fibroblast proliferation through RAS pathway signalling. There is no established or proposed intersection between SOS1/GINGF-driven fibrotic pathology and the ALK/RET/ROS1 kinase axis that Alectinib targets.

The TxGNN model’s high score for this indication most likely arises from indirect multi-hop connections within the biomedical knowledge graph — for example, pathways connecting “fibroproliferative lesion → kinase activation → ALK” — rather than any direct mechanistic relationship. The biological plausibility of applying an ALK inhibitor to a benign, non-kinase-driven, hereditary fibrotic condition is assessed as extremely low. This result is considered a probable false positive driven by graph topology rather than genuine pharmacological rationale, and should not be acted upon without substantial preclinical validation.

Clinical Trial Evidence

Currently no related clinical trials registered for Alectinib in gingival fibromatosis.

Literature Evidence

Currently no related literature available for Alectinib in gingival fibromatosis.

Cytotoxicity

Alectinib is an antineoplastic agent indicated for the treatment of ALK-positive NSCLC; the following cytotoxicity assessment applies.

Item	Content
Cytotoxicity Classification	Targeted Therapy — Second-generation ALK/RET/ROS1 tyrosine kinase inhibitor (not conventional cytotoxic)
Myelosuppression Risk	Low — haematological toxicities are uncommon; anaemia reported in Phase 3 trials at low frequency; not myelosuppressive in the traditional cytotoxic sense
Emetogenicity Classification	Low
Monitoring Items	Full blood count (FBC), liver function tests (LFTs), renal function, serum creatine phosphokinase (CPK/CK), blood pressure, resting heart rate (bradycardia risk), and ECG
Handling Protection	Standard oral targeted therapy precautions apply; cytotoxic handling procedures per institutional policy are recommended given the antineoplastic classification

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Important note for Australian clinicians: Alectinib is not currently registered with the TGA in Australia (0 ARTG entries). Safety information should be sourced from international regulatory agency product information (e.g., FDA [Alecensa®] or EMA-approved PI), the DrugBank record (DB11363), or published Phase 3 trial safety data. Key adverse effects documented in published trials include: constipation, myalgia, peripheral oedema, elevated CPK, anaemia, elevated liver transaminases, bradycardia, and photosensitivity. Weight gain (up to ~10% of patients) has also been reported in real-world cohorts.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical, preclinical, or mechanistic evidence linking Alectinib to gingival fibromatosis. The condition is driven by SOS1/GINGF gene mutations affecting fibroblast proliferation — a pathway with no established relationship to ALK, RET, or ROS1 kinase signalling — making this TxGNN prediction a likely knowledge graph false positive with negligible translational value in its current form.

To proceed, the following would be needed:

Preclinical validation: Demonstrate ALK pathway activity (e.g., ALK expression, phosphorylation, or rearrangement) in gingival fibromatosis cell lines or patient-derived tissue specimens
Molecular profiling: Screen GF tissue for any incidental ALK/RET rearrangements that might create a targetable niche subpopulation
MOA data acquisition: Retrieve full kinase inhibition and pharmacodynamic profile from DrugBank (DB11363) to identify any off-target mechanisms that could be relevant to fibrotic pathology
TGA registration pathway assessment: If biological rationale is subsequently established, determine whether compassionate access, TGA Special Access Scheme (SAS), or a clinical trial pathway would be appropriate for Australian patients
Safety baseline: Obtain full TGA-equivalent Product Information from FDA or EMA sources prior to any clinical consideration

⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All TxGNN predictions are model-generated hypotheses and must be interpreted in the context of available biological and clinical evidence.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.